Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 25, Issue 9, Pages 1189-1191Publisher
WILEY
DOI: 10.1111/ene.13687
Keywords
biomarkers; chitinase 3-like 1; mild cognitive impairment; multiple sclerosis; neurofilament light chain
Categories
Funding
- Bayer Schering Pharma
- Merk Serono
- Biogen-Idec
- Teva Pharmaceuticals
- Genzyme
- Novartis
- Sanofi-Aventis
- Biogen Idec
- Bayer
- Merck-Serono
- Teva Pharmaceutical Industries Ltd
- Almirall
Ask authors/readers for more resources
Background and purpose: Chitinase 3-like 1 (CHI3L1) and neurofilament light chain (NF-L) are promising biomarkers of disability in multiple sclerosis (MS). However, their role in cognitive dysfunction remains elusive. Here, we aimed to correlate cerebrospinal fluid (CSF) levels of CHI3L1 and NF-L with cognitive status in MS. Methods: Fifty one recently diagnosed patients were cognitively evaluated and CSF was collected. Levels of CHI3L1 and NF-L were determined by ELISA. Spearman's partial correlation coefficient was performed. Results: After adjusting cognitive scores by age, anxiety and EDSS, association was detected between CHI3L1 levels and Trail Making Test A (rs = 0.348; p = 0.016) and between NF-L levels and Word List Generation (rs = -0.324; p = 0.025). Conclusion: High levels of CSF CHI3L1 and NF-L are associated with cognitive impairment in the early phases of MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available